Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy

Neoplasia

Volumn 12, Issue 11, 2010, Pages 928-940

  Tang, Terence C ^a   Man, Shan ^a   Xu, Ping ^a   Francia, Giulio ^a   Hashimoto, Kae ^a   Emmenegger, Urban ^a,b   Kerbel, Robert S ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; COMPLEMENTARY DNA; SORAFENIB; UFT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RELAPSE; CANCER TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LONG TERM CARE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; TOXICITY TESTING; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 78449235351     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10804     Document Type: Article

References (47)

1. Bergers G and Hanahan D (2008).Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592-603.
2. Rini BI and Atkins MB (2009). Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10, 992-1000.
3. Kerbel RS (2008). Tumor angiogenesis. N Engl J Med 358, 2039-2049.
4. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, and Szczylik C (2009). Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115, 61-67.
5. Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, and Keilholz U (2009). Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76, 350-354.
6. Di Lorenzo G, Carteni G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, et al. (2009). Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27(27), 4469-4474.
7. Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
8. Rapisarda A and Melillo G (2009). Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 12, 74-80.
9. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, et al. (2004). Scheduledependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64, 6845-6848.
10. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732.
11. Yu JL, Rak JW, Coomber BL, Hicklin DJ, and Kerbel RS (2002). Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528.
12. Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, et al. (2004). Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2, 36-42.
13. Glade BJ, Cooney EM, Kandel JJ, and Yamashiro DJ (2004). Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7, 289-300.
14. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, and Ferrara N (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21-34.
15. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, and Ferrara N (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25, 911-920.
16. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, et al. (2010). Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9(6), 1525-1535.
17. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, and The BT (2010). Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70, 1063-1071.
18. Llovet JM and Bruix J (2009). Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol 27, 833-835.
19. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, and Yang TS (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 10, 25-34.
20. Tang TC, Man S, Lee CR, Xu P, and Kerbel RS (2010). Impact of metronomic UFT/ cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 12, 264-274.
21. Shih IM, Torrance C, Sokoll LJ, Chan DW, Kinzler KW, and Vogelstein B (2000). Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin. Nat Med 6, 711-714.
22. Francia G, Emmenegger U, Lee CR, Shaked Y, Folkins C, Mossoba M, Medin JA, Man S, Zhu Z, and Witte L (2008). Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther 7, 3452-3459.
23. Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, and Kerbel RS (2009). Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res 15, 6358-6366.
24. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, and Kerbel RS (2006). Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66, 3386-3391.
25. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, and Lynch M (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf an VEGFand PDGFreceptor tyrosine kinase signaling. MolCancer Ther 7, 3129-3140.
26. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, and Carter C (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66, 11851-11858.
27. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, et al. (2007). Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59, 561-574.
28. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, et al. (2004). A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350, 1713-1721.
29. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, and Yamada Y (1999). UFTand its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5, 2185-2191.
30. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, and Kerbel RS (2002). Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62, 2731-2735.
31. Pietras K and Hanahan D (2005). A multitargeted, metronomic, and maximumtolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23, 939-952.
32. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
33. Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, and van Herpen CM (2009). The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 48, 621-624.
34. Wolter P, Beuselinck B, Pans S, and Schoffski P (2009). Flare-up: an often\ unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 48, 621-624.
35. La Vine DB, Coleman TA, Davis CH, Carbonell CE, and Davis WB (2009). Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 33(3), 217-220.
36. Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, Halbrook J, Kesicki EA, Kashishian A, and Hallahan DE (2005). DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 65, 4987-4992.
37. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, et al. (2009). Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 53, 594-598.
38. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, and Brodie AM (2008). Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 68, 4518-4524.
39. Chen HX and Cleck JN (2009). Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6, 465-477.
40. Verheul HM and Pinedo HM (2007). Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7, 475-485.
41. Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, et al. (2009). Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer:National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol 27, 1368-1374.
42. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, and Kerbel RS (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.
43. Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, and Makuuchi M (2006). Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 44, 891-895.
44. Di MG, Fazio N, Nole F, Della VP, Lorizzo K, Goldhirsch A, and Farris A (2007). Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma. Acta Oncol 46, 1205-1206.
45. Matsuda M, Shiba S, Asakawa M, Kono H, and Fujii H (2009). Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expression of fluoropyrimidine metabolism enzymes in the primary tumor. Int J Clin Oncol 14, 245-248.
46. Ueda H, Tanaka H, Kida Y, Fukuchi H, and Ichinose M(2008). Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma. Oncol Rep 19, 1355-1361.
47. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, and Cheng AL (2010). Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53(1), 126-131.